文献速递神经肿瘤功能神经外科

Remebot机器人辅助立体定向活检:496例颅内病变回顾性分析

Diagnostic yield and safety of Remebot robot-assisted stereotactic biopsy: a 496-case retrospective analysis of intracranial lesions.
PubMed 文献 · J Neurosurg · 2026-07-24

该研究回顾性分析496例接受Remebot辅助立体定向脑活检的患者,总体诊断率为85.9%(426/496),围手术期并发症率为1.8%(9/496)。多因素分析显示深部病变采样(OR 0.51,95%CI 0.27-0.94;p=0.034)和年轻年龄(OR 0.98,95%CI 0.97-0.99;p=0.006)是非诊断结果的独立预测因素。

要点

  • Remebot辅助立体定向活检诊断率85.9%,并发症率1.8%。
  • 深部病变采样和年轻年龄与非诊断结果独立相关。
  • 性别和病变位置(幕上/幕下、脑干受累)与诊断率无关。

核心结论

  • Remebot辅助立体定向活检诊断率高、并发症率低,与国际机器人平台相当。
  • 深部病变采样和年轻年龄增加非诊断结果风险,性别和病变位置不影响诊断率。

研究设计与样本

  • 单中心回顾性分析2023至2024年连续496例接受Remebot辅助立体定向脑活检的患者。
  • 收集人口学、临床、影像和病理数据,采用逻辑回归分析非诊断活检的预测因素。

主要发现

  • 总体诊断率为85.9%(426/496),最常见病理为高级别胶质瘤(32.7%)和血液系统恶性肿瘤(20.4%)。
  • 多因素分析显示深部病变采样(OR 0.51,95%CI 0.27-0.94;p=0.034)和年轻年龄(OR 0.98,95%CI 0.97-0.99;p=0.006)是非诊断结果的独立预测因素。
  • 性别、病变位置(幕上vs幕下)和脑干受累与诊断率无关。
  • 围手术期并发症率为1.8%(9/496),出血占77.8%,所有并发症均发生于男性患者,多见于高级别胶质瘤患者。

临床怎么用

  • Remebot系统整合规划、自动注册和紧凑模块化设计, workflow优势明显,支持微创神经外科诊断。
  • 对于深部病变和年轻患者,应警惕非诊断结果风险,必要时考虑优化采样策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the diagnostic yield, safety, and workflow advantages of the Remebot system in intracranial stereotactic biopsies. METHODS: The authors retrospectively analyzed 496 consecutive patients who underwent Remebot-assisted stereotactic brain biopsy at a single institution between 2023 and 2024. Demographic, clinical, radiological, and pathological data were collected. Logistic regression analysis was used to identify predictors of nondiagnostic biopsy. Model performance was evaluated using McFadden's pseudo-R2 and receiver operating characteristic analysis. Perioperative complications were defined and graded according to the Common Terminology Criteria for Adverse Events (version 5.0). RESULTS: The overall diagnostic yield was 85.9% (426/496), with high-grade glioma (32.7%) and hematological malignancies (20.4%) as the most common pathologies. Multivariate analysis identified deep lesion sampling (OR 0.51, 95% CI 0.27-0.94; p = 0.034) and younger age (OR 0.98, 95% CI 0.97-0.99; p = 0.006) as independent predictors of nondiagnostic results. Sex, lesion location (supratentorial vs infratentorial), and brainstem involvement were not associated with yield. The perioperative complication rate was 1.8% (9/496), with hemorrhage accounting for 77.8% of events. All complications occurred in male patients, predominantly in those with high-grade glioma. The Remebot system demonstrated notable workflow advantages, including integrated planning, automated registration, and compact modular design. CONCLUSIONS: Remebot-assisted stereotactic biopsy achieved a high diagnostic yield and low complication rate, comparable with that of international robotic platforms. Deep lesion sampling and younger age were found to increase the risk of nondiagnostic results, whereas sex and lesion location did not. The system's integrated workflow, automated registration, and cost-efficient accessibility broaden its clinical applicability and support its role as a reliable tool for minimally invasive neurosurgical diagnosis.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wang K, Yan F, Wang Y, et al. Diagnostic yield and safety of Remebot robot-assisted stereotactic biopsy: a 496-case retrospective analysis of intracranial lesions. J Neurosurg. 2026. PMID: 42497454. doi:10.3171/2026.2.JNS251592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。